Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.41 |
| ▸ | KIT | P10721 | 11/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | CSF1R | P07333 | 1/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 3/20 | 0.35 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.35 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.35 |
| ▸ | CCNC | P24863 | 1/20 | 0.34 |
| ▸ | CDK8 | P49336 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28862448 | 1.00 | MKNK1 (0.41) | MKNK1KITPDPK1RPS6KB1TP53 | |
| SCHEMBL22918645 | 0.80 | KIT (0.51) | MKNK1KITLCKCSF1RPDGFRB | |
| SCHEMBL29614180 | 0.80 | KIT (0.51) | MKNK1KITLCKCSF1RPDGFRB | |
| SCHEMBL29709020 | 0.80 | KIT (0.51) | MKNK1KITLCKCSF1RPDGFRB | |
| SCHEMBL22918729 | 0.72 | EGFR (0.35) | TP53EGFRERBB2 | |
| SCHEMBL28862431 | 0.72 | PRMT5 (0.38) | KITCSF1RCCNCCDK8 | |
| SCHEMBL29615433 | 0.72 | PRMT5 (0.38) | KITCSF1RCCNCCDK8 | |
| SCHEMBL22919004 | 0.68 | KIT (0.71) | KITLCKCSF1RPDGFRBPDGFRA | |
| SCHEMBL22918855 | 0.68 | KIT (0.33) | MKNK1KITLCKCSF1RPDGFRB | |
| SCHEMBL28862468 | 0.67 | GPR55 (0.48) | KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109697-A1 | 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL)-PYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2026-04-23 | — | — | US | disclosed |
| CN-118955500-A | 4- (Imidazo [1,2-a ] pyridin-3-yl) -pyrimidine derivatives | 默克专利股份公司 | 2024-11-15 | — | — | CN | disclosed |
| US-20220267320-A1 | 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL)-PYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2022-08-25 | — | — | US | disclosed |
| EP-4003992-A1 | 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL) -PYRIMIDINE DERIVATIVES | Merck Patent GmbH (DE) | 2022-06-01 | — | — | EP | disclosed |
| CN-114174293-A | 4- (imidazo [1,2-a ] pyridin-3-yl) -pyrimidine derivatives | 默克专利股份公司 | 2022-03-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109697-A1 | 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL)-PYRIMIDINE DERIVATIVES | CHUK, CNKSR1, KIT | MKNK1 1238/4885KIT 3/4885PDPK1 815/4885 |
| US-20220267320-A1 | 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL)-PYRIMIDINE DERIVATIVES | NCOA3, NCOR1, NCOA4 | MKNK1 1025/4885KIT 273/4885PDPK1 1318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.